Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4152W HIGH $1.85
Volume
6.42 K
Value Traded
18.29 K
Short % Float
0.91%
-11.48%Week
-21.04%1 Month
-40.73%3 Month
-40.43%6 Month
-99.97%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.26 M
EPS (TTM)
-0.40
P/E Ratio
-
Ent. Value
-11.99 M
Total Shares
7.58 M
Float Shares
6.44 M
Insiders
14.98%
Institutions
7.11%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MBIO Catalyst Timeline
Dated clinical, regulatory and corporate events for Mustang Bio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Mustang Bio, Inc.
495Total events
2Upcoming
77Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 2
TBD
T3Enrollment Update
Subscribe to view catalyst details
TBD
T3Enrollment Update
Subscribe to view catalyst details
Event history 50
◆Topline ReadoutMB-106FiledClinical Data
Top-line data from pivotal Phase 2 WM trial expected as early as mid-2026
Waldenstrom macroglobulinemiasource ↗
▲Orphan Drug DesignationMB-101Designation
FDA granted Orphan Drug Designation for MB-101
recurrent diffuse and anaplastic astrocytoma and glioblastomasource ↗
◆Trial InitiationMB-109Trial
Initiation of novel clinical trial for MB-109 (MB-108 + MB-101) expected in second half of 2025
recurrent glioblastoma and high-grade astrocytomassource ↗
▼Restructuring LayoffsCorporate
Exit of manufacturing facility lease and sale of fixed assets to AbbVie
▼Reverse Stock SplitCorporate
1-for-50 reverse stock split to comply with Nasdaq minimum bid price
◆Trial InitiationMB-106FiledTrial
Initiate pivotal Phase 2 trial in at least one additional B-cell malignancy in 2025
B-cell malignancysource ↗
▲Orphan Drug DesignationMB-108Designation
FDA grants Orphan Drug Designation for MB-108 in malignant glioma
malignant gliomasource ↗
◆Trial InitiationMB-106FiledTrial
Phase 1 investigator-sponsored trial initiation in autoimmune diseases
autoimmune diseasessource ↗
◆First Patient DosedMB-106FiledTrial
First patient enrollment in Phase 1 autoimmune trial
autoimmune diseasessource ↗
▼Equity OfferingCorporate
Closing of $2.5 million registered direct offering priced at-the-market
▲Poster PresentationMB-106FiledPresentation
Updated data from WM cohort presented at EHA2024
Waldenstrom macroglobulinemiasource ↗
▲Full ResultsMB-106FiledClinical Data
Favorable efficacy and safety data from complete WM cohort
Waldenstrom macroglobulinemiasource ↗
◆First Patient DosedMB-106FiledTrial
First patient expected to be treated in pivotal Phase 2 WM trial
Waldenstrom macroglobulinemiasource ↗
◆Trial InitiationMB-106FiledTrial
Initiation of registrational trial for WM (58 patients, 20 sites in North America)
relapsed or refractory Waldenstrom macroglobulinemiasource ↗
▲First Patient DosedMB-106FiledTrial
First patient in pivotal Phase 2 WM trial expected to be treated in mid-2024
Waldenstrom macroglobulinemiasource ↗
▲PublicationMB-101Presentation
Data from Phase 1 trial of MB-101 published in Nature Medicine
high-grade gliomasource ↗
◆Oral PresentationPresentation
Mustang Bio CEO to participate in fireside chat at B. Riley Securities 4th Annual Oncology Conference
▲Full ResultsMB-101Clinical Data
Phase 1 results published in Nature Medicine 2024: 2 complete responses lasting 7.5 and 66+ months
recurrent glioblastomasource ↗
◆Trial InitiationMB-109Trial
Plan to initiate Phase 1 trial of MB-109 in 2024, subject to resource allocation
recurrent glioblastoma and high-grade astrocytomasource ↗
◆End Of Phase 1 MeetingMB-106FiledFDA Meeting
End-of-Phase 1 meeting with FDA to discuss registrational trial design for WM
relapsed or refractory Waldenstrom macroglobulinemiasource ↗
▲RMATMB-106FiledDesignation
Mustang anticipates requesting RMAT designation for WM from FDA in 2024
Waldenstrom macroglobulinemiasource ↗
◆First Patient DosedMB-106FiledTrial
First pivotal Phase 2 patient with WM to be treated potentially in Q1 2024
Waldenstrom macroglobulinemiasource ↗
◆Trial InitiationMB-106FiledTrial
Initiate pivotal phase 2 trial in at least one additional B-cell malignancy later in 2024
B-cell malignancysource ↗
◆PreprintPresentation
Anticipated publication of proof-of-concept research for in vivo CAR-T platform in murine tumor model in 2024
◆First Patient DosedMB-117Trial
First patients expected to be treated in 2024 in investigator-sponsored trial for newborns with XSCID using MB-117
X-linked severe combined immunodeficiency (XSCID) in newbornssource ↗
◆First Patient DosedMB-217Trial
First patients expected to be treated in 2024 in investigator-sponsored trial for previously transplanted XSCID patients using MB-217
X-linked severe combined immunodeficiency (XSCID) in previously transplanted patientssource ↗
◆Poster PresentationMB-106FiledPresentation
Poster presentation of interim Phase 1/2 data at 65th ASH Annual Meeting
relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemiasource ↗
◆Oral PresentationMB-106FiledPresentation
Additional safety and efficacy data from MB-106 multicenter trial to be presented at ASH 2023
relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemiasource ↗
▲Oral PresentationMB-106FiledPresentation
Initial data from multicenter Phase 1/2 trial of MB-106 presented at ASH 2023
Waldenstrom macroglobulinemia, follicular lymphoma, hairy cell leukemia variantsource ↗
◆Timing GuidancePresentation
Landlord to review lease assignment request after CFIUS clearance (additional 30 days)
◆AbstractMB-106FiledPresentation
Abstract posted on ASH Annual Meeting website
relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemiasource ↗
▼Equity OfferingCorporate
Closing of $4.4 million registered direct offering priced at-the-market
▼Equity OfferingCorporate
Mustang Bio announces $4.4 million registered direct offering priced at-the-market
▲IND ClearanceMB-109IND
FDA acceptance of IND for MB-109
recurrent glioblastoma and high-grade astrocytomasource ↗
▲IND ClearanceMB-109IND
FDA accepted IND for MB-109 to initiate Phase 1 trial
recurrent glioblastoma and high-grade astrocytomasource ↗
▼Equity OfferingCorporate
Registered direct offering completed in October 2023 for ~$4.4M gross proceeds
◆Topline ReadoutMB-106FiledClinical Data
Additional safety and efficacy data from multicenter trial expected in Q4 2023
indolent lymphomasource ↗
◆Oral PresentationMB-106FiledPresentation
Updated data from indolent lymphoma arm expected in Q4 2023
indolent lymphomasource ↗
◆Oral PresentationPresentation
2023 Cantor Fitzgerald Global Healthcare Conference panel presentation
Past FDA Catalysts and PDUFA Decisions
How MBIO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-12-31 | MB-106 | Phase 1/2 data readout | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every MBIO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| MB-106 | Waldenstrom macroglobulinemia | Phase 1/2 | 2024-06-17 | 90% overall response rate, 3 complete responses, 2 very good partial responses, 4 partial responses, 1 patient remains in complete remission at 31 monthsRead More | Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T TherapyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Litchman Manuel MDDirector, Officer (President, CEO and Interim CFO) | Disposition | -19 1,615 held | $0.75 | 04/24/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MBIO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 0 % | 13.00 K | 33.32 K |
MBIO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MBIO ranks across every disease it competes in
Competitive Position is a premium feature
See how MBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMBIO News
MBIO▲ +180.7%on this news
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
Mustang Bio has been granted Orphan Drug Designation by the FDA for MB-101, a CAR T-cell therapy targeting IL13Ra2, aimed at treating recurrent astrocytomas and glioblastoma. The designation is based on positive results from a Phase 1 trial, where 50% of patients achieved stable disease or better. The company is also exploring a combination therapy with MB-108 to enhance treatment efficacy. However, further development is contingent on securing additional funding.
Read more →MBIO▼ -9.4%on this news
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
Mustang Bio, Inc. has announced that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement. This follows a formal notice from Nasdaq confirming that the company meets all criteria for continued listing. Mustang previously satisfied the minimum bid price requirement, indicating a positive trajectory for the company.
Read more →MBIO▼ -27%on this news· ran to -38% by day 3shared move
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
Mustang Bio has announced the exit of its manufacturing facility lease in Worcester, Massachusetts, and the sale of fixed assets to AbbVie for $1 million. The company anticipates saving around $2 million in cash expenses over the next two years. Mustang is focusing on advancing its clinical trials, particularly with MB-109 for treating recurrent glioblastoma, expected to initiate in late 2025.
Read more →MBIOMustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
Mustang Bio, Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirement. Following a recent public offering, the company believes it has met the necessary stockholders' equity for continued listing. However, a formal compliance determination from Nasdaq is still pending, and there is uncertainty regarding the outcome.
Read more →MBIO▲ +5.4%on this newsshared move
Mustang Bio Announces Closing of $8 Million Public Offering
Mustang Bio, Inc. has closed an $8 million public offering, issuing over 2.6 million shares and accompanying warrants. The proceeds will be used for working capital and corporate purposes. The offering was facilitated by H.C. Wainwright & Co. and follows the SEC's approval of their registration statement. However, the company faces various risks, including funding needs and potential delays in clinical trials.
Read more →MBIOMustang Bio Announces Pricing of $8 Million Public Offering
Mustang Bio, Inc. announced the pricing of a public offering of 2,657,807 shares at $3.01 each, along with warrants. The gross proceeds are expected to be around $8 million, which will be utilized for working capital and corporate purposes. The offering is subject to stockholder approval and customary closing conditions.
Read more →MBIO▼ -35.8%on this news· ran to -50% by day 3
Mustang Bio Announces Reverse Stock Split
Mustang Bio, Inc. announced a 1-for-50 reverse stock split of its common stock, effective January 16, 2025. This decision, approved by the Board of Directors, aims to meet Nasdaq's minimum bid price requirement. Following the split, the number of outstanding shares will decrease from approximately 64.8 million to about 1.3 million. Stockholders will receive cash payments for any fractional shares.
Read more →MBIOMustang Bio Receives Positive Listing Determination from Nasdaq
Mustang Bio, Inc. announced that the Nasdaq Hearings Panel approved its request for an extension to demonstrate compliance with continued listing criteria on The Nasdaq Capital Market. The company has until January 31, 2025, to meet the $1.00 bid price requirement and until February 18, 2025, for the $2.5 million stockholders' equity requirement. Mustang is exploring options to meet these criteria, but there is no guarantee of success. The company, focused on cell therapies for cancer treatment, faces financial uncertainties and risks associated with clinical trials.
Read more →MBIOMustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
Mustang Bio has received Orphan Drug Designation from the FDA for MB-108, an HSV-1 oncolytic virus aimed at treating malignant glioma. The designation denotes special incentives, such as tax credits and market exclusivity. Ongoing Phase 1 clinical trials indicate that MB-108 is well tolerated in recurrent glioblastoma patients. The company aims to combine MB-108 with MB-101 CAR-T cell therapy to improve therapeutic outcomes, contingent on future funding and strategic partnerships.
Read more →MBIOMustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
Mustang Bio, Inc. has announced the exercise of certain existing warrants, resulting in gross proceeds of approximately $4 million. The agreement involves the purchase of nearly 17 million shares at an exercise price of $0.237 per share. Additionally, new warrants for the purchase of over 33 million shares will be issued, with a higher exercise price of $0.27 each. The funds will primarily be used for working capital and general corporate purposes, with the transaction expected to close on or around October 25, 2024.
Read more →MBIOMustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mustang Bio, Inc. has successfully closed a $2.5 million registered direct offering priced at-the-market under Nasdaq rules. The offering involved the issuance of 6,130,000 shares at $0.41 per share and included unregistered warrants. The net proceeds from this offering are intended for working capital and general corporate purposes. This move may help the company to continue its focus on developing cell therapies for difficult-to-treat cancers.
Read more →MBIO▼ -34.1%on this newsshared move
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mustang Bio, Inc. has announced a registered direct offering to issue 6,130,000 shares of common stock at a price of $0.41 per share, aiming to raise approximately $2.5 million. The offering, set to close around June 21, 2024, will include unregistered warrants to purchase additional shares. The funds will primarily support general corporate purposes and working capital. H.C. Wainwright & Co. is the exclusive placement agent for this offering.
Read more →MBIO▲ +476.9%on this news· ran to +554% by day 1shared move
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
Mustang Bio has announced favorable updated data from its Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T therapy for Waldenstrom macroglobulinemia (WM). The trial reported a 90% overall response rate, with durable remissions observed, demonstrating the potential of MB-106 in treating this challenging blood cancer. Despite the promising results, the future of the MB-106 program is dependent on securing additional funding and developing strategic partnerships.
Read more →MBIO▲ +12.6%on this news
Mustang Bio Announces Closing of $4 Million Public Offering
Mustang Bio, Inc. announced the successful closing of a public offering, raising approximately $4 million from the sale of shares and warrants. This funding will be used for working capital and other corporate needs. The company also amended existing warrants to lower their exercise price significantly. If fully exercised, these warrants could result in an additional $12 million in gross proceeds for the company.
Read more →MBIOMustang Bio Announces Pricing of $4 Million Public Offering
Mustang Bio, Inc. has announced the pricing of a public offering, raising $4 million through the sale of approximately 16.9 million shares of common stock and associated warrants. The shares are priced at $0.237 each, with various series of warrants attached. The net proceeds from this offering will be allocated for working capital and corporate needs, as the offering is expected to close on or around May 2, 2024. Additionally, Mustang Bio plans to amend existing warrants from a previous offering to match this new exercise price. The company emphasizes their commitment to developing effective therapies during this funding acquisition.
Read more →MBIO▲ +10.6%on this news
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
Mustang Bio, Inc. is planning to expand its CAR T-cell therapy platform with MB-106, targeting autoimmune diseases. They are in discussions with Fred Hutchinson Cancer Center to initiate a Phase 1 investigator-sponsored clinical trial in late 2024, leveraging promising safety and efficacy data from previous studies. The company believes that its CAR T-cell therapy can lead to improved patient outcomes in this new application, although there are inherent risks in the clinical trial process and the need for substantial funding.
Read more →MBIO▼ -7.2%on this news· ran to -20% by day 3
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Mustang Bio, Inc. reported its full-year financial results for 2023, highlighting significant developments in its clinical trials, particularly with MB-106. The company plans to initiate a registrational CAR-T trial targeting Waldenstrom macroglobulinemia, with expectations for FDA interactions in 2024. Despite demonstrating promising clinical data and partnerships, Mustang has faced a considerable decline in cash reserves and reported a net loss for the year. The upcoming RMAT designation from the FDA could enhance the development process for their therapies.
Read more →MBIOMustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
Mustang Bio, Inc. will take part in the upcoming B. Riley Securities 4th Annual Oncology Conference on January 18, 2024. CEO Manuel Litchman is set to participate in a fireside chat, indicating a focus on sharing advancements in cell and gene therapies for treating difficult cancers and rare diseases. The event may enhance Mustang's visibility among investors and stakeholders in the oncology sector. A replay of the chat will be available following the event.
Read more →MBIO▼ -7.1%on this news
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
Mustang Bio presented updated clinical data for MB-106 at the ASH Annual Meeting, highlighting a robust safety and efficacy profile. Data from nine patients show a 100% complete response rate among those with follicular lymphoma, with no occurrences of severe cytokine release syndrome or neurotoxicity. This new data builds on prior results from a single-center trial, indicating consistent therapeutic benefits and feasibility of outpatient treatment. The company is planning to finalize a Phase 2 dose level and move forward with regulatory meetings early in 2024.
Read more →MBIOMustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Mustang Bio, Inc. reported third-quarter 2023 financial results highlighting advances in its clinical programs, particularly for MB-106, which has shown promising safety and efficacy in treating certain B-cell malignancies. The company plans to present further data at the upcoming ASH Annual Meeting and expects to pursue an accelerated registration strategy for Waldenstrom macroglobulinemia. Additionally, Mustang's investigational drug MB-109 received FDA clearance to initiate a Phase 1 trial for glioblastoma. Despite these advancements, Mustang's financial position has worsened, reflected in a significant year-over-year loss and decreasing cash reserves.
Read more →About Mustang Bio, Inc.
Headquarters95 SAWYER RD, WALTHAM, MA, 02453
BIOPHARMAWATCH ELITE PLUS
Trade the next MBIO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime